Bibliographic Details
| Title: |
Comparative effectiveness of sotrovimab versus no treatment in non-hospitalised high-risk COVID-19 patients in north west London: a retrospective cohort study |
| Authors: |
Stephen J Brett, Vishal Patel, Sophie Young, Bethany Levick, Daniel C Gibbons, Tahereh Kamalati, Myriam Drysdale, Evgeniy R Galimov, Marcus James Yarwood, Jonathan D Watkins, Benjamin F Pierce, Emily J Lloyd, William Kerr, Helen J Birch |
| Source: |
BMJ Open Respiratory Research, Vol 11, Iss 1 (2024) |
| Publisher Information: |
BMJ Publishing Group, 2024. |
| Publication Year: |
2024 |
| Collection: |
LCC:Medicine
LCC:Diseases of the respiratory system |
| Subject Terms: |
Medicine, Diseases of the respiratory system, RC705-779 |
| More Details: |
Background We assessed the effectiveness of sotrovimab vs no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance.Methods Retrospective cohort study using the Discover dataset in North West London. Included patients were non-hospitalised, aged ≥12 years and met ≥1 National Health Service highest-risk criterion for sotrovimab treatment. We used Cox proportional hazards models to compare HRs of 28-day COVID-19-related hospitalisation/death between highest-risk sotrovimab-treated and untreated patients. Age, renal disease and Omicron subvariant subgroup analyses were performed.Results We included 599 sotrovimab-treated patients and 5191 untreated patients. Compared with untreated patients, the risk of COVID-19 hospitalisation/death (HR 0.50, 95% CI 0.24, 1.06; p=0.07) and the risk of COVID-19 hospitalisation (HR 0.43, 95% CI 0.18, 1.00; p=0.051) were both lower in the sotrovimab-treated group; however, statistical significance was not reached. In the ≥65 years and renal disease subgroups, sotrovimab was associated with a significantly reduced risk of COVID-19 hospitalisation, by 89% (HR 0.11, 95% CI 0.02, 0.82; p=0.03) and 82% (HR 0.18, 95% CI 0.05, 0.62; p=0.007), respectively.Conclusions Risk of COVID-19 hospitalisation in sotrovimab-treated patients aged ≥65 years and with renal disease was significantly lower compared with untreated patients. Overall, risk of hospitalisation was also lower for sotrovimab-treated patients, but statistical significance was not reached. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2052-4439 |
| Relation: |
https://bmjopenrespres.bmj.com/content/11/1/e002238.full; https://doaj.org/toc/2052-4439 |
| DOI: |
10.1136/bmjresp-2023-002238 |
| Access URL: |
https://doaj.org/article/63c9ad243a8c40aca8bd08c0e7ef1fac |
| Accession Number: |
edsdoj.63c9ad243a8c40aca8bd08c0e7ef1fac |
| Database: |
Directory of Open Access Journals |
